Frederick Locke
Physician · H. Lee Moffitt Cancer Center and Research Institute
Credentials: · · · ·
History
- 2005–2007
Medical Oncology
- 2002–2005
Internal Medicine
Research
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Review · Biology of Blood and Marrow Transplantation · 2019 · 3,048 citations
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Case report · Nature Reviews Clinical Oncology · 2018 · 1,951 citations
- MJ
91 papers
- TN
72 papers
52 papers
- MA
45 papers
- DH
43 papers
- FK
42 papers
- AL
39 papers
39 papers
Grants
- 2022–2027
National Cancer Institute · R01
PI · $3.8M · h. Lee Moffitt Cancer Ctr & Res Inst
- 1998–2027
Moffitt Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $47.6K · h. Lee Moffitt Cancer Ctr & Res Inst
- 2015–2020
Breaking Immune Tolerance to Survivin in Multiple Myeloma
National Cancer Institute · K23
Contact PI · $820.8K · h. Lee Moffitt Cancer Ctr & Res Inst
Clinical trials
- 2025–2028
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Principal investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
- 2021–2027
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
Principal investigator · Active not recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
- 2016–2018
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
Principal investigator · Completed · Early phase 1
H. Lee Moffitt Cancer Center and Research Institute
- 2013–2016
Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant
Principal investigator · Completed
H. Lee Moffitt Cancer Center and Research Institute